Skip to main content
SpringerLink
Log in

Oncology—Digestive Tract

  • Chapter
Clinical PET and PET/CT

  • 1378 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliography

Gastroesophageal Cancer

  1. Arslan N, Miller TR, Dehdashti F, et al. Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol 2002; 4:301–10.

    PubMed  Google Scholar 

  2. Bakheet SM, Amin T, Alia AG, et al. F-18 FDG uptake in benign esophageal disease. Clin Nucl Med 1999; 24:995–7.

    PubMed  CAS  Google Scholar 

  3. Berger KL, Nicholson SA, Dehdashti F, Siegel BA. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol 2000; 74:1005–1008.

    Google Scholar 

  4. Block MI, Patterson GA, Sundaresan RS, et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 1997; 64:770–6.

    Article  PubMed  CAS  Google Scholar 

  5. Brucher BL, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001; 233:300–9.

    PubMed  CAS  Google Scholar 

  6. Chin BB, Wahl RL. 18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies. Gut 2003; 52Suppl 4:iv23–9.

    PubMed  Google Scholar 

  7. Choi JY, Lee KH, Shim YM, et al. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nucl Med 2000; 41:808–15.

    PubMed  CAS  Google Scholar 

  8. Couper GW, McAteer D, Wallis F, et al. Detection of response to chemotherapy using positron emission tomography in patients with esophageal and gastric cancer. Br J Surg 1998; 85:1403–1406.

    Article  PubMed  CAS  Google Scholar 

  9. De Potter T, Flamen P, Van Cutsem E, et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 2002; 29:525–9.

    PubMed  Google Scholar 

  10. DeYoung CM, Suntharalingam M, Line BR, et al. The ability of whole body FDG18 PET imaging to predict pathologic response to induction chemoradiotherapy in locally advanced esophageal cancer. A prospective phase II trial. Int J Radiat Oncol Biol Phys 2003; 57(2 Suppl):S165–6.

    Google Scholar 

  11. Downey RJ, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003; 21:428–32.

    Article  PubMed  Google Scholar 

  12. Flamen P, Lerut A, Van Cutsem E, et al. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 2000; 120:1085–92.

    Article  PubMed  CAS  Google Scholar 

  13. Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000; 18:3202–10.

    PubMed  CAS  Google Scholar 

  14. Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced esophageal cancer. Ann Oncol 2002; 13:361–8.

    Article  PubMed  CAS  Google Scholar 

  15. Flanagan FL, Dehdashti F, Siegel BA, et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol. 1997; 168:417–24.

    PubMed  CAS  Google Scholar 

  16. Fukunaga T, Okazumi S, Koide Y, et al. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 1998; 39:1002–7.

    PubMed  CAS  Google Scholar 

  17. Hoffmann M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) dose not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999; 10:1185–1189.

    Article  PubMed  CAS  Google Scholar 

  18. Ichiya Y, Kuwabara Y, Otsuka M, et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 1991; 32:1655–60.

    PubMed  CAS  Google Scholar 

  19. Jadvar H, Cham DK, Conti PS. Diagnostic evaluation of esophageal carcinoma with [F-18]-FDG PET/CT. Mol Imaging Biol 2003; 5:188.

    Google Scholar 

  20. Jadvar H, Tatlidil R, Garcia AA, Conti PS. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol 2003; 58:215–21.

    Article  PubMed  CAS  Google Scholar 

  21. Kato H, Kuwano H, Nakajima M, et al. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 2002; 184:279–83.

    Article  PubMed  Google Scholar 

  22. Kato H, Kuwano H, Nakajima M, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 2002; 94:921–8.

    PubMed  Google Scholar 

  23. Kato H, Takita J, Miyazaki T, et al. Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma. Anticancer Res 2003; 23:3263–72.

    PubMed  CAS  Google Scholar 

  24. Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 2001; 92:634–641.

    Article  PubMed  CAS  Google Scholar 

  25. Kim K, Park SJ, Kim BT, et al. Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. Ann Thorac Surg 2001; 71:290–4.

    PubMed  CAS  Google Scholar 

  26. Kneist W, Schreckenberger M, Bartenstein P, et al. Positron emission tomography for staging esophageal cancer: does it lead to a different therapeutic approach? World J Surg 2003; 27:1105–12.

    Article  PubMed  Google Scholar 

  27. Koga H, Sasaki M, Kuwabara Y, et al. An analysis of the physiological FDG uptake pattern in the stomach. Ann Nucl Med 2003; 17:733–8.

    Article  PubMed  CAS  Google Scholar 

  28. Kole AC, Plukker JT, Nieweg OE, Vaalburg W. Positron emission tomography for staging of esophageal and gastroesophageal malignancy. Br J Cancer 1998; 78:521–527.

    PubMed  CAS  Google Scholar 

  29. Lerut T, Flamen P, Ectors N, et al. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg 2000; 232:743–52.

    PubMed  CAS  Google Scholar 

  30. Lin EC, Lear J, Quaife RA. Metastatic peritoneal seeding patterns demonstrated by FDG positron emission tomographic imaging. Clin Nucl Med 2001; 29:249–250

    Google Scholar 

  31. Luketich JD, Friedman DM, Weigel TL, et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999; 68:1133–6.

    PubMed  CAS  Google Scholar 

  32. Luketich JD, Schauer PR, Meltzer CC, et al. Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg 1997; 64:765–9.

    Article  PubMed  CAS  Google Scholar 

  33. McAteer D, Wallis F, Couper G, et al. Evaluation of 18F-FDG positron emission tomography in gastric and esophageal carcinoma. Br J Radiol 1999; 72:525–529.

    PubMed  CAS  Google Scholar 

  34. Meltzer CC, Luketich JD, Friedman D, et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med 2000; 25:882–7.

    Article  PubMed  CAS  Google Scholar 

  35. Noguchi Y, Marat D, Saito A, et al. Expression of facilitative glucose transporters in gastric tumors. Hepatogastroenterology 1999; 46:2683–89.

    PubMed  CAS  Google Scholar 

  36. Nunez RF, Yeung HW, Macapinlac H. Increased F-18 FDG uptake in the stomach. Clin Nucl Med 1999; 24:281–282.

    Article  PubMed  CAS  Google Scholar 

  37. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003; 21:4604–10.

    Article  PubMed  CAS  Google Scholar 

  38. Pectasides D, Mylonakis A, Kostopoulou M, et al. CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma. Am J Clin Oncol 1997; 20:348–353.

    Article  PubMed  CAS  Google Scholar 

  39. Rankin SC, Taylor H, Cook GJ, Mason R. Computed tomography and positron emission tomography in the pre-operative staging of esophageal carcinoma. Clin Radiol 1998; 53:659–65.

    PubMed  CAS  Google Scholar 

  40. Rasanen JV, Sihvo EI, Knuuti MJ, et al. Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann Surg Oncol 2003; 10:954–60.

    PubMed  Google Scholar 

  41. Rice TW. Clinical staging of esophageal carcinoma. CT, EUS, and PET. Chest Surg Clin N Am 2000; 10:471–85.

    PubMed  CAS  Google Scholar 

  42. Rodriguez M, Ahlstrom H, Sundin A, et al. [18F] FDG PET in gastric non-Hodgkin’s lymphoma. Acta Oncol 1997; 36:577–584.

    Article  PubMed  CAS  Google Scholar 

  43. Schwarz RE, Zagala-Nevarez K. Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapy. Ann Surg Oncol 2002; 9:394–400.

    Article  PubMed  Google Scholar 

  44. Shiraishi N, Inomata M, Osawa N, Yasuda K, Adachi Y, Kitano S. Early and late recurrence after gastrectomy for gastric carcinoma. Univariate and multivariate analyses. Cancer 2000; 89:255–261.

    Article  PubMed  CAS  Google Scholar 

  45. Skehan SJ, Brown AL, Thompson M, et al. Imaging features of primary and recurrent esophageal cancer at FDG PET. Radiographics 2000; 20:713–23.

    PubMed  CAS  Google Scholar 

  46. Stahl A, Ott K, Weber WA, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003; 30:288–95.

    Article  PubMed  CAS  Google Scholar 

  47. van Westreenen HL, Heeren PA, Jager PL, et al. Pitfalls of positive findings in staging esophageal cancer with F-18-fluorodeoxyglucose positron emission tomography. Ann Surg Oncol 2003; 10:1100–5.

    Article  PubMed  Google Scholar 

  48. Wallace MB, Nietert PJ, Earle C, et al. An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. Ann Thorac Surg 2002; 74:1026–32.

    Article  PubMed  Google Scholar 

  49. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19:3058–65.

    PubMed  CAS  Google Scholar 

  50. Wren SM, Stijns P, Srinivas S. Positron emission tomography in the initial staging of esophageal cancer. Arch Surg 2002; 137:1001–6.

    PubMed  Google Scholar 

  51. Yeung HW, Macapinlac H, Karpeh M, et al. Accuracy of FDG-PET in gastric cancer. preliminary experience. Clin Positron Imaging 1998; 1:213–221.

    PubMed  Google Scholar 

  52. Yeung HW, Macapinlac HA, Mazumdar M, et al. FDG-PET in esophageal cancer. Incremental value over computed tomography. Clin Positron Imaging 1999; 2:255–260.

    PubMed  Google Scholar 

  53. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000; 87:236–242.

    Article  PubMed  CAS  Google Scholar 

  54. Yoon YC, Lee KS, Shim YM, et al. Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study. Radiology 2003; 227:764–70.

    PubMed  Google Scholar 

  55. Yoshioka T, Yamaguchi K, Kubota K, et al. Evaluation of 18F-FDG PET in patients with metastatic or recurrent gastric cancer. J Nucl Med 2003; 44:690–9.

    PubMed  CAS  Google Scholar 

Colorectal Cancer

  1. Abdel-Nabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinoma with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998; 206:755–60.

    PubMed  CAS  Google Scholar 

  2. Akhurst T, Larson SM. Positron emission tomography imaging of colorectal cancer. Semin Oncol 1999; 26:577–83.

    PubMed  CAS  Google Scholar 

  3. Beets G, Penninckx F, Schiepers C, et al. Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994; 81:1666–70.

    PubMed  CAS  Google Scholar 

  4. Delbeke D, Vitola J, Sandler MP, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997; 38:1196–1201.

    PubMed  CAS  Google Scholar 

  5. Donckier V, Van Laethem JL, Goldman S, et al. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol 2003; 84:215–23.

    PubMed  Google Scholar 

  6. Drenth JP, Nagengast FM, Oyen WJ. Evaluation of (pre-)malignant colonic abnormalities: endoscopic validation of FDG-PET findings. Eur J Nucl Med 2001; 28:1766–9.

    Article  PubMed  CAS  Google Scholar 

  7. Falk PM, Gupta NC, Thorson AG, et al. Positron emission tomography for preoperative staging of colorectal carcinoma. Dis Colon Rectum 1994; 37:153–6.

    PubMed  CAS  Google Scholar 

  8. Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996; 14:700–8.

    PubMed  CAS  Google Scholar 

  9. Flamen P, Stroobants S, Van Cutsem E, et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol 1999; 17:894–901.

    PubMed  CAS  Google Scholar 

  10. Flanagan FL, Dehdashti F, Qgunbiyi OA, et al. Utility of FDG PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998; 227:319–23.

    Article  PubMed  CAS  Google Scholar 

  11. Gambhir SS, Valk P, Shepherd J, et al. Cost effective analysis modeling of the role of FDG PET in the management of patients with recurrent colorectal cancer. J Nucl Med 1997; 38:90P.

    Google Scholar 

  12. Guillem J, Calle J, Akhurst T, et al. Preoperative assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 2000; 43:18–24.

    PubMed  CAS  Google Scholar 

  13. Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000; 41:1177–89.

    PubMed  CAS  Google Scholar 

  14. Imdahl A, Reinhardt MJ, Nitzsche EU, et al. Impact of 18F-FDG positron emission tomography for decision making in colorectal cancer recurrences. Arch Surg 2000; 385:129–134.

    CAS  Google Scholar 

  15. Ito K, Kato T, Tadokoro M, et al. Recurrent rectal cancer and scar: differentiation with PET and MR imaging. Radiology 1992; 182:549–52.

    PubMed  CAS  Google Scholar 

  16. Jadvar H, Johnson DL, Abella-Columna E, et al. Staging colorectal carcinoma with FDG PET at the time of initial diagnosis. Radiology 1997; 205(P):399.

    Google Scholar 

  17. Kim EE, Chung SK, Haynie TP, et al. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. Radiographics 1992; 12:269–79.

    PubMed  CAS  Google Scholar 

  18. Koike I, Ohmura M, Hata M, et al. FDG-PET scanning after radiation can predict tumor regrowth three months later. Int J Radiat Oncol Biol Phys 2003; 57:1231–8.

    Article  PubMed  Google Scholar 

  19. Libutti SK, Alexander HR Jr, Choyke P, et al. A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann Surg Oncol 2001; 8:779–86.

    PubMed  CAS  Google Scholar 

  20. Meta J, Seltzer M, Schiepers C, et al. Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician’s perspective. J Nucl Med 2001; 42:586–90.

    PubMed  CAS  Google Scholar 

  21. Ohue M, Sekimoto M, Fukunaga H, et al. A case of curative resection of local recurrence after abdominosacral resection of recurrent rectal cancer based on the diagnosis of PET/CT fusion images. Gan To Kagaku Ryoho 2003; 30:1829–32.

    PubMed  Google Scholar 

  22. Schiepers C, Penninckx F, De Vadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995; 21:517–22.

    Article  PubMed  CAS  Google Scholar 

  23. Staib L, Schirrmeister H, Reske SN, et al. Is (18F)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg 2000; 180:1–5.

    Article  PubMed  CAS  Google Scholar 

  24. Strauss LG, Clorius JH, Schlag P, et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989; 170:329–32.

    PubMed  CAS  Google Scholar 

  25. Tatlidil R, Jadvar H, Bading JR, Conti PS. Incidental colonic [F-18]fluorodeoxyglucose uptake: correlation with colonoscopy and histopathology. Radiology 2002; 224:783–7.

    PubMed  Google Scholar 

  26. Valk PE, Abella-Columna E, Haseman MK, et al. Whole-body PET imaging with F-18-fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999; 134:503–11.

    PubMed  CAS  Google Scholar 

  27. Vitola JV, Delbeke D, Meranze SG, et al. Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer 1996; 78:2216–22.

    Article  PubMed  CAS  Google Scholar 

  28. Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage metastatic colorectal carcinoma to the liver. Am J Surg 1996; 171:21–6.

    Article  PubMed  CAS  Google Scholar 

  29. Whiteford MH, Whiteford HM, Yee LF, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 2000; 43:759–67.

    Article  PubMed  CAS  Google Scholar 

  30. Zhuang H, Hickeson M, Chacko TK, et al. Incidental detection of colon cancer by FDG positron emission tomography in patients examined for pulmonary nodules. Clin Nucl Med 2002; 27:628–32.

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag London Limited

About this chapter

Cite this chapter

(2005). Oncology—Digestive Tract. In: Clinical PET and PET/CT. Springer, London. https://doi.org/10.1007/1-84628-100-8_8

Download citation

  • DOI: https://doi.org/10.1007/1-84628-100-8_8

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-838-1

  • Online ISBN: 978-1-84628-100-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation